Completed MK-3795 (PT2385) for the Treatment of Von Hippel-Lindau Disease-Associated Clear Cell Renal Cell Carcinoma (MK-3795-003) NCT03108066 Conditions Abnormalities, Multiple, Adenocarcinoma, Angiomatosis, +35 more Locations National Institutes of Health Clinical Center — Bethesda, Maryland, United States View Trial Details
Active, Not Recruiting A Phase 2 Study of Belzutifan (PT2977, MK-6482) for the Treatment of Von Hippel Lindau (VHL) Disease-Associated Renal Cell Carcinoma (RCC) (MK-6482-004) NCT03401788 Conditions Abnormalities, Multiple, Angiomatosis, Cardiovascular Diseases, +14 more Locations National Institutes of Health Clinical Center — Bethesda, Maryland, United States Massachusetts General Hospital — Boston, Massachusetts, United States University of Michigan — Ann Arbor, Michigan, United States University of Pennsylvania Medical Center — Philadelphia, Pennsylvania, United States View more locations Show fewer locations Loading locations... View Trial Details
